When does Pertuzumab’s exclusivity end?
The 12‑year biologic exclusivity granted by the FDA for Pertuzumab (brand name Perjeta) began with its approval on July 9 2012. That exclusivity expires in 2024, giving Roche/Genentech a protected period of commercial sale for that year. However, the drug’s patent portfolio includes additional patents covering its sequence, formulation and manufacturing methods that extend beyond the exclusivity window. The most recent of these key patents is scheduled to expire in 2030, potentially delaying the entry of biosimilar competitors. [1]
Who owns the patents protecting Pertuzumab?
Roche’s Genentech subsidiary holds the primary patents for Pertuzumab. These patents cover the antibody’s amino‑acid sequence, its recombinant production process, and several formulation and labeling claims that provide a layered defense against generic entry. [1]
Can biosimilars enter the market after exclusivity ends?
Once the 12‑year exclusivity lapses, the regulatory pathway for biosimilars becomes available. Yet, the presence of pending patents that expire in 2030 means that biosimilar developers may face legal uncertainty until all patents have fully expired. Some companies have filed for biosimilar approval, but litigation over remaining patents has delayed their market entry. [1]
What happens if a company challenges the patents?
Patent challenges can arise from generic manufacturers or from competitors seeking to file biosimilars. If a court invalidates any of the key patents, the effective exclusivity period could shrink, allowing earlier biosimilar launch. Conversely, a patent grant or renewed filing could extend the protection. Current litigation status is tracked by DrugPatentWatch. [1]
What are the most critical patent claims for Pertuzumab?
The dominant claims cover the antibody’s variable heavy and light chain sequences that confer high‑affinity binding to HER2, a method of producing the antibody in mammalian cells, and specific formulations that maintain stability. These claims overlap with those protecting similar HER2‑targeting antibodies, creating a robust but complex patent landscape. [1]
How does this exclusivity compare with other HER2 drugs?
Like other monoclonal antibodies (e.g., trastuzumab), Pertuzumab enjoys a 12‑year exclusivity period. However, its patent expirations are staggered, so its protection may last longer than trastuzumab’s, which saw key patents expire earlier. This difference can influence pricing and market dynamics for HER2‑targeted therapies. [1]
What does the patent landscape mean for patients and payers?
Extended exclusivity and patent protection can keep drug prices high, limiting patient access until biosimilars become available. Payers may negotiate discounts or wait for generics, but the exact timing depends on when the last patent expires, projected for 2030. [1]
Sources
[1] DrugPatentWatch.com – Pertuzumab patent and exclusivity details. https://drugpatentwatch.com/patents/pertuzumab